Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider, and a Huron Capital portfolio company, announced the publication of its second annual Environmental, Social and Governance Report. The report provides information on the performance and management of Albireo Energy's commitments to address environmental, social and governance priorities, while building long-term value for the company's stakeholders. The Albireo Energy 2022 ESG Re.

Albireo Energy Publishes 2022 ESG Report

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

Ipsen e xtends e xpiration d ate of t ender o ffer for Albireo Pharma , Inc.  to 1 March 202 3

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixibat) indication for patients with Alagille syndrome (ALGS). As defined by the FDA, the Priority Review timeline is 6 months and the agency will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. With completed submissions for Bylvay in the U.S. and EU for use in patients with ALGS, the Company anticipates approvals in mid-2023.

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

Evoqua Water Technologies

Concert Pharma

Leap Therapeutics

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor  New York, NY 10007 (212) 682-3025  (888) 593-4771 stockinfo@weisslawllp.com Evoqua Water Technologies Corp. (NYSE: AQUA) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem").

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

CinCor Pharma

There's nothing like a big-premium buyout to send a company's share price to the moon.

Why These Two Biotech Stocks Blasted Higher This Week

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.

Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "Company") (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer.

SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Albireo Pharma, Inc. (NASDAQ: ALBO), relating to its proposed sale to Ipsen. Under the terms of the agreement, ALBO shareholders are expected to receive $42.00 in cash per share they own, plus one Contingent Value Right worth a deferred $10.00 per share.

ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO

Wilmington, Delaware--(Newsfile Corp. - January 9, 2023) - Rigrodsky Law, P.A. is investigating Albireo Pharma, Inc. ("Albireo") (NASDAQ CM: ALBO) regarding possible breaches of fiduciary duties and other violations of law related to Albireo's agreement to be acquired by Ipsen Biopharmaceuticals, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-albireo-pharma-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Albireo Pharma, Inc. Buyout

Ipsen (IPN, IPSEY) and Albireo (ALBO) announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo. These are the details.

Why Ipsen Is Buying Albireo (ALBO) (IPSEY)

Duck Creek Technologies

The market is moving higher, and these small companies are helping.

2 Tiny Nasdaq Stocks Making Major Merger Moves Monday

MILWAUKEE , Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Albireo (Nasdaq: ALBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen.  Click here to learn how to join the action https://www.ademilaw.com/case/albireo-pharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Albireo Pharma, Inc. (NASDAQ: ALBO) to Ipsen is fair to Albireo shareholders. Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration's approval of Bylvay in the Biliary Atresia indication by December 31, 2027.

ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders

PARIS & BOSTON--( BUSINESS WIRE )--Regulatory News:

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo's common stock. The restricted stock units were granted as an inducement material to Dr. Streck's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each restricted stock unit is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The restricted stock units are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D.

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the Committee Economic Health Products (CEPS) has approved reimbursed access to Bylvay (odevixibat) in France following a favorable clinical assessment from the Haute Autorité de Santé (HAS) for the treatment of progressive familial intrahepatic cholestasis (PFIC) types 1 and 2 (except for the BSEP3 subtype). A potent, oral, once-daily, non-systemic ileal bile acid transport inhibitor, Bylvay has minimal systemic exposure and acts locally in the small intestine as a treatment for PFIC, a rare and devastating disorder that affects young children and causes progressive, life-threatening liver disease. Bylvay received from the HAS Transparency Committee an Important SMR for its medical benefit and a Moderate ASMR III for its improvement in medical benefit.

Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022. Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT.

Albireo to Participate in Jefferies London Healthcare Conference

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&D Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Miriam Nolan - Jefferies Brian Skorney - Baird Ritu Baral - Cowen Seamus Fernandez - Guggenheim Tim Lugo - William Blair Andreas Argyrides - Wedbush Securities Thomas Yip - H. C. Wainwright Operator Good afternoon.

Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.

Albireo Reports Q3 2022 Financial Results and Business Update

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, presented new data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022, being held November 4 – 8, 2022 in Washington, D.C. Across three oral presentations, including two late-breakers, and six posters, the Company provided evidence of early, rapid, and sustained efficacy with Bylvay (odevixibat) treatment in patients with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

— Eight projects selected for inaugural year of the program

News for Albireo Pharma Stock (ALBO)